Global SERD Therapeutics Market Size is valued at USD 1339.0 Mn in 2024 and is predicted to reach USD 2108.7 Mn by the year 2034 at a 4.8% CAGR during the forecast period for 2025-2034.
Selective estrogen receptor degrader (SERD) is a type of drug which downregulates the estrogen receptor. SERD treats estrogen receptor-positive breast cancer. SERD therapy can be used as both monotherapies and in combination with other therapeutic agents. Many key market players are engaged in developing new breast cancer therapies that would propel the growth of this market.
Major driving factors in the SERD therapeutics market are the increasing need for SERD therapies, the high prevalence of breast cancer, the rising number of clinical trials, and increasing investments by key players in the development of promising treatments. Furthermore, advanced medical technologies, growth in the population, and a growing number of health-conscious people will enhance the growth of the SERD therapeutics market during the forecast period. However, the high price of devices, complex procedures, lack of strict government laws, and resistance to endocrine Therapy are limiting the growth of this market.
The SERD therapeutics market is segmented into Products, Route of Administration, Indication and Region. On the basis of Products, market is segmented into Faslodex, Elacestrant, Camizestrant (AZD9833), Giredestrant (GDC-9545), Imlunestrant (LY3484356), Other Pipeline Products. The Route of Administration segments consists of Intramuscular, Oral, Infusion, Subcutaneous, Parenteral, and Other. On the basis of Indications, segment includes ER-positive, HER2-negative, ESR1-mutated, advanced or metastatic breast cancer and Other.
Regionally, the SERD therapeutics market is divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America, followed by Europe, holds the maximum share of this market due to increased research and development expenditure, major market players, and the fast adaption of advanced technologies.
Major vital Players in the SERD therapeutics market are Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Dr Reddy’s Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT Labs, Inc, Hoffmann-La Roche AG, InventisBio, Novartis AG, Radius Health, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Zenopharm LLC., Zentalis Pharmaceuticals, and List of Other Prominent Players.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 1339.0 Mn |
| Revenue Forecast In 2034 | USD 2108.7 Mn |
| Growth Rate CAGR | CAGR of 4.8% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Products, By Route of Administration, By Indication |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Dr. Reddy’s Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT Labs, Inc, Hoffmann-La Roche AG, InventisBio, Novartis AG, Radius Health, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Zenopharm LLC., Zentalis Pharmaceuticals, Genentech, Olema Pharmaceuticals, Aragon Pharmaceuticals, Sun Pharma Advanced Research Company, Shandong Luoxin Pharmaceutical Zeno Alpha, Atossa Therapeutics, Evestra and Others. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Products
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Route Of Administration
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Indication
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Region
North America SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
Europe SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
Asia Pacific SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
Latin America SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
Middle East & Africa SERD therapeutics market revenue (US$ Million) by Country, 2023-2034
Competitive Landscape
Latest Strategic Developments
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.